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11-Hydroxysteroid Dehydrogenase Type 1 Is
Expressed in Neutrophils and Restrains an
Inflammatory Response in Male Mice
Agnes E. Coutinho,* Tiina M. J. Kipari,* Zhenguang Zhang, Cristina L. Esteves,
Christopher D. Lucas, James S. Gilmour, Scott P. Webster, Brian R. Walker,
Jeremy Hughes, John S. Savill, Jonathan R. Seckl, Adriano G. Rossi,
and Karen E. Chapman
Centre for Cardiovascular Science (A.E.C., T.M.J.K., Z.Z., C.L.E., J.S.G., S.P.W., B.R.W., J.R.S., K.E.C.) and
Medical Research Council Centre for Inflammation Research (A.E.C., C.D.L., J.S.G., J.H., J.S.S., A.G.R.),
Queen’s Medical Research Institute, University of Edinburgh, Edinburgh EH16 4TJ, United Kingdom
Endogenous glucocorticoid action within cells is enhanced by prereceptor metabolism by 11-
hydroxysteroid dehydrogenase type 1 (11-HSD1), which converts intrinsically inert cortisone and
11-dehydrocorticosterone into active cortisol and corticosterone, respectively. 11-HSD1 is highly
expressed in immune cells elicited to the mouse peritoneum during thioglycollate-induced peri-
tonitis and is down-regulated as the inflammation resolves. During inflammation, 11-HSD1-de-
ficient mice show enhanced recruitment of inflammatory cells and delayed acquisition of macro-
phage phagocytic capacity. However, the key cells in which 11-HSD1 exerts these effects remain
unknown. Here we have identified neutrophils (CD11b,Ly6G,7/4 cells) as the thioglycollate-
recruited cells that most highly express 11-HSD1 and show dynamic regulation of 11-HSD1 in
these cells during an inflammatory response. Flow cytometry showed high expression of 11-HSD1
in peritoneal neutrophils early during inflammation, declining at later states. In contrast, expres-
sion in blood neutrophils continued to increase during inflammation. Ablation of monocytes/
macrophages by treatment of CD11b-diphtheria-toxin receptor transgenic mice with diphtheria
toxin prior to thioglycollate injection had no significant effect on 11-HSD1 activity in peritoneal
cells, consistent with neutrophils being the predominant 11-HSD1 expressing cell type at this time.
Similar to genetic deficiency in 11-HSD1, acute inhibition of 11-HSD1 activity during thioglycollate-
induced peritonitis augmented inflammatory cell recruitment to the peritoneum. These data suggest
that neutrophil 11-HSD1 increases during inflammation to contribute to the restraining effect of
glucocorticoids upon neutrophil-mediated inflammation. In human neutrophils, lipopolysaccharide
activation increased 11-HSD1 expression, suggesting the antiinflammatory effects of 11-HSD1 in
neutrophils may be conserved in humans. (Endocrinology 157: 2928–2936, 2016)
Neutrophils are one of the first leukocytes recruitedto an inflammatory site and are essential to fight
microbial infections (1). They are short lived, surviving
only a few hours in the circulation, and are released in
huge numbers daily from the bone marrow as terminally
differentiated cells. Neutrophils are recruited to sites of
inflammation by microbial-derived products (eg, lipo-
polysaccharide [LPS]) and host-derived mediators such
as cytokines (primarily IL-1, IL-6, and TNF-) and
chemokines (eg, CXC chemokine ligand-8 and CXC
chemokine ligand-5).
Endogenous glucocorticoids play a critical role in
controlling inflammatory responses (2). Neutrophils,
monocytes, and macrophages are all important targets
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for the antiinflammatory effects of glucocorticoids. The
circadian rhythm in glucocorticoid release contributes
to the normal circadian variation in inflammatory re-
sponses, including modulation of neutrophil recruit-
ment (3). Furthermore, dysregulated hypothalamic-pi-
tuitary-adrenal axis activity is likely a contributory
factor in chronic inflammatory conditions (4). Al-
though neutrophils are important glucocorticoid tar-
gets, conflicting reports exist regarding their glucocor-
ticoid sensitivity (5–7). Neutrophilic inflammation, as
in some chronic lung diseases, is frequently relatively
glucocorticoid resistant (8) for reasons that are unclear.
Glucocorticoid sensitivity may differ between activated
and nonstimulated neutrophils, and indeed, glucocor-
ticoids delay neutrophil apoptosis (9), although not un-
der severe hypoxia or in the presence of certain inflam-
matory mediators (10).
An important level of control over endogenous glu-
cocorticoid action is exerted by the activity of 11-hy-
droxysteroid dehydrogenase (11-HSD), an enzyme
that interconverts intrinsically inert glucocorticoids
(cortisone, 11-dehydrocorticosterone) and their active
forms (cortisol, corticosterone) (11). The type 2 isozyme,
11-HSD2, which inactivates glucocorticoids, is not ex-
pressed in immune cells analyzed from healthy humans
and mice (although it becomes expressed here in neoplasia
and certain other pathological states [12–14]). However,
the type 1 isozyme, 11-HSD1 is widely expressed in im-
mune cells in which it acts predominantly as an oxore-
ductase, increasing intracellular glucocorticoid levels. It
can thus modulate and shape an ongoing immune or in-
flammatory response (reviewed in reference 15).
Normally in rodents, the levels of 11-HSD1 sub-
strate, 11-dehydrocorticosterone, are low in the circu-
lation, but they are increased markedly when plasma
corticosterone levels are elevated (16), for example, af-
ter the activation of the hypothalamic-pituitary-adrenal
axis or corticosterone administration. Under conditions
of chronic corticosterone excess, 11-HSD1 becomes a
major modifier of the ensuing adverse metabolic effects
(17). 11-HSD1 expression is frequently increased at
sites of inflammation, including in humans, and is in-
duced in fibroblasts and other cell types by proinflam-
matory cytokines, particularly IL-1 and TNF- (15).
Expression of 11-HSD1 is very low in monocytes, but
it is rapidly induced upon differentiation to macro-
phages, with macrophage activation being a powerful
regulator of its expression (reviewed in reference 15).
11-HSD1 expression has been reported in human
neutrophils (18), although human neutrophils under-
going constitutive apoptosis are
completely lacking in 11-HSD1
oxoreductase activity (14).
We previously showed that
11-HSD1 activity is high in in-
flammatory cells recruited to the
peritoneum during thioglycollate-
induced peritonitis in mice and is
down-regulated as the inflamma-
tion resolves (19). During sterile
peritonitis, 11-HSD1-deficient mice
show enhanced recruitment of in-
flammatory cells (20) and delayed
acquisition of macrophage phago-
cytic capacity (19). However, the key
cells in which 11-HSD1 exerts
these effects were unknown. Here we
have identified activated neutrophils
as the cells most highly expressing
11-HSD1 during thioglycollate-in-
duced peritonitis and show 11-HSD1
expression in these cells is dynamically
regulated during an inflammatory re-
sponse. Furthermore, we have investi-
gated the effects of acute inhibition of
11-HSD1 upon neutrophilic inflam-
mation during peritonitis.
A B
C D
Figure 1. High 11-HSD1 expression in inflammatory cells elicited to the peritoneum early
during peritonitis. A, Peritoneal cell counts in lavages collected 0, 4, 24, and 96 hours after the
injection of 300 L of 10% thioglycollate. Flow cytometry was used to determine the number of
11-HSD1 peritoneal cells (as a percentage of total cells) (B) and the MFI of cellular 11-HSD1
expression (C) during the course of peritonitis. D, Real-time PCR measurement of Hsd11b1
mRNA levels (relative to Hprt) in total peritoneal cells 4, 24, and 96 hours after the injection of
300 L of 10% thioglycollate, expressed in arbitrary units (AU), with levels at 4 hours arbitrarily
set to 1.0. Data are means  SEM and were analyzed by an ANOVA, with Tukey’s post hoc tests.
*, P  .05, **, P  .01, ***, P  .001, compared with 0 hours; §, P  .001 compared with 4
hours; ¶, P  .001 compared with 24 hours (n  6–8/group).
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Materials and Methods
Animals
To avoid interanimal variability that would be introduced
due to differences in the stage of estrous in females, male mice
were used. Male C57BL/6 mice (12–14 wk) bred on-site or
purchased from Harlan were housed under controlled condi-
tions (12 h light, 12 h dark cycle at 21°C) with unrestricted
access to standard rodent chow and water. All experiments on
animals were approved by the local ethics committee and were
performed in accordance with the UK Home Office Animals
(Scientific Procedures) Act of 1986.
Thioglycollate-induced sterile peritonitis
Peritonitis was induced in mice by ip injection of 0.3 mL of
10% thioglycollate as described (19). Blood was collected
from the tail vein into 3.9% sodium citrate. Peritoneal cells
were collected by lavage with 5 mL cold PBS and counted using
a hemocytometer. Bone marrow cells were collected by flush-
ing femurs with 5 mL PBS. Blood and bone marrow cells were
counted using a NucleoCassette and a NucleoCounter NC-
100 (ChemoMetec). For the 11-HSD1-inhibitor experi-
ments, vehicle (saline with 2% dimethylsulfoxide) or com-
pound UE2316 (10 mg/kg) (21) was administered by ip
injection, the night before and 1 hour prior to thioglycollate
injection. Peritoneal cells were collected 4 hours later.
Isolation of mouse neutrophils
After lavage to collect peritoneal cells 24 hours after the thio-
glycollate injection, neutrophils were isolated by incubation with
Ly6G-phycoerythrinantibody (BioLegend) followedby incubation
with antiphycoerythrin secondary antibody magnetic beads (Milte-
nyi Biotec) according to the manufacturer’s instructions. Generally,
isolated peritoneal neutrophils were 96% or more pure, based on
histochemical staining of cytocentrifuge preparations and flow cy-
tometric analysis (Supplemental Figure 1).
Isolation and treatment of human neutrophils
Neutrophils were isolated from the peripheral blood of
healthy volunteers (Lothian Research Ethics Committee, 08/
S1103/38) by dextran sedimentation and discontinuous Percoll
gradient and resuspended in Iscove’s modified Dulbecco’s medium
(PAA) with 10% autologous serum at 5  106/mL (37°C, 5%
CO2) as described (22). Neutrophil purity was routinely greater
than 96% with 1%–3% contaminating eosinophils. Neutrophils
(106 cells) were seeded in RPMI 1640 medium containing 10%
charcoal-stripped fetal bovine serum and were treated with
100 ng/mL LPS for 4 hours prior to RNA extraction and
analysis.
Flow cytometry
Cells from the peritoneum, bone marrow, and blood were
incubated in PBS with 10% mouse serum
(Sigma-Aldrich) for 20 minutes on ice to
block nonspecific binding. Ly6G-phyco-
erythrin (PECy7), CD11b-PerCP Cy5.5,
or Pacific Blue (BioLegend), 7/4-Alexa-
647 (AbD Serotec) antimouse antibodies
were added to the cell suspensions at con-
centrations recommend by the supplier
and incubated on ice for 30 minutes in
the dark. 11-HSD1 sheep-derived anti-
body, generated in-house (23), was used
in combination with donkey antisheep
secondary antibody (Alexa Fluor 488;
Invitrogen). Cells were treated with a fix-
ation and permeabilization kit (Fix and
Perm; Invitrogen) according to the man-
ufacturer’s instructions to allow for in-
tracellular staining with the 11-HSD1
antibody (Supplemental Figure 2). Blood
and bone marrow cells were treated with
BD lysis buffer (BD Biosciences) to elim-
inate red blood cells. Fluorescence was
determined by FACScalibur using Cell-
quest (Becton Dickinson UK Ltd) or 5L
LSR Fortessa using FACSDiva (Becton
Dickinson UK Ltd) and analyzed using
FlowJo software (Treestar).
11-HSD1 activity assay
11-HSD1 reductase activity in peri-
toneal immune cells was measured as de-
scribed (19). Briefly, cells were incubated
in medium containing 200 nM 11-dehy-
drocorticosterone with trace amounts of
[3H]11-dehydrocorticosterone (made as
described [19]). Steroids were extracted
A B
C D
Figure 2. Thioglycollate-elicited neutrophils express 11-HSD1. A, Flow cytometry was used to
determine the number of neutrophils (black bars; Ly6G7/4CD11b) and monocytes (white bars;
Ly6G7/4CD11b) in peritoneal lavages collected 0, 4, 24, or 96 hours after the injection of 300 L
of 10% thioglycollate. Data are means  SEM and were analyzed by an ANOVA, with Tukey’s post
hoc tests, ***, P  .001, compared with 0 hours; §, P  .001 compared with 4hours; ¶, P  .001
compared with 24 hours (n  6–8 mice/group). B, Representative histogram (of eight mice) from
flow cytometry showing strong positive staining of 11-HSD1 in neutrophils (black line), to a lesser
degree in monocytes (dark gray line), and negative control staining (light gray) in cells lavaged 24
hours after the thioglycollate injection. C, 11-HSD1 activity assay performed on freshly isolated
neutrophils lavaged 24 hours after the thioglycollate injection: conversion of 200 nM [3H]-11-
dehydrocorticosterone to corticosterone, expressed as picomoles corticosterone per hour per 106
cells. Values are mean  SEM of three independent pools of peritoneal cells (each from three mice)
and were analyzed using an ANOVA with Tukey’s post hoc tests. **, P  .01, ***, P  .001,
compared with total cells. D, Real-time PCR measurement of 11-HSD1 mRNA levels in purified
neutrophils collected 24 hours after the thioglycollate injection. Each value represents a single pool of
cells from five mice and is in arbitrary units (AU), with the level in total cells arbitrarily set to 1.0.
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in triplicate at various time points and analyzed by HPLC as
described (24).
CD11b-diphtheria toxin ablation
Briefly, 24 hours prior to thioglycollate treatment, diphtheria
toxin (25 ng/g body weight) was administered iv to CD11b-DTR
transgenic mice to deplete monocytes/macrophages, as described
(25). Quantification of cytocentrifuged cells collected 4 hours
after thioglycollate injection showed a greater than 95% de-
crease in monocytes/macrophages in diphtheria toxin-treated
CD11b-DTR transgenic mice. 11-HSD1 reductase activity was
measured in total peritoneal cells 4 hours after the thioglycollate
injection.
RNA extraction and real-time PCR analysis
Total mRNA was extracted from cells using Trizol (Invit-
rogen), and 1 g mRNA was reverse transcribed using Super-
Script III (Invitrogen). Specific mRNAs were quantified by
real-time PCR (quantitative PCR) on a LightCycler 480
(Roche) as previously described (26, 27). The following prim-
ers (Invitrogen) and probes (Universal Probe Library; Roche)
were used for PCR: Hsd11b1, probe 1, with forward, 5	-
TCTACAAATGAAGAGTTCAGACCAG-3	 and reverse, 5	-
GCCCCAGTGACAATCACTTT-3	; Cd11b, probe 16, with
forward, 5	-AAGGATGCTGGGGAGGTC-3	 and reverse,
5	-GTCATAAGTGACAGTGCTCTGGA-3	; Hprt, probe
95, with forward, 5	-TCCTCCTCAGACCGCTTTT-3	 and
reverse, 5	-CCTGGTTCATCATCGCTAATC-3	; Sell, probe
45, with forward, 5	-TGCAGAGAGACCCAGCAAG-3	 and
reverse, 5	-CAGACCCACAGCTTCAGGAT-3	, and Anxa1,
probe 95, with forward, 5	-GTGAACGTCTTCACCA
CAATTC-3	 and reverse, 5	-GTACTTTCCGTAATTCTGAAA
CACTCT-3	. For humans, the following primers were used:
HSD11B1 (Hs01547870_m1) and RPL32 (Hs00851655_g1)
(Invitrogen).
Statistics
Statistical analysis was performed using a Student’s t test, a
one-way ANOVA followed by Dunnett’s, or a Tukey’s multiple
comparison test, as appropriate. Significance was set at P  .05.
Unless stated otherwise, values are means  SEM.
Results
The cells highly expressing 11-HSD1 recruited to
the peritoneum during peritonitis are neutrophils
After an ip injection of thioglycollate in C57BL/6
mice, the number of cells expressing 11-HSD1 in-
creased, as did the total peritoneal cell number. Both
decreased as the inflammation resolved (Figure 1, A and
B), consistent with previous measurements of 11-
HSD1 activity in thioglycollate-elicited peritoneal cells
(19). In addition, compared with resident peritoneal
cells (0 h), cellular expression of 11-HSD1 (measured
as mean fluorescence intensity [MFI]) was increased in
recruited cells 4 and 24 hours after thioglycollate injec-
tion but was reduced as the inflammation resolved, with
lower levels by 96 hours than in resident peritoneal cells
(Figure 1C). The down-regulation of 11-HSD1 MFI
with resolution of inflammation at 96 hours may ac-
count for the reduction in 11-HSD1 cells at this time
point (Figure 1B). Levels of the encoding Hsd11b1
mRNA were high in the total peritoneal cells isolated 4
hours after thioglycollate injection, reducing dramati-
cally by 24 hours (Figure 1D). These data confirm our
previous findings of high 11-HSD1 activity in cells
recruited to the peritoneum during inflammation and
also show the increase in activity is paralleled by high
Hsd11b1 mRNA levels, which subsequently decrease
during the resolution phase.
Both neutrophils (Ly6G,7/4,CD11b) and mono-
cytes (Ly6G,7/4,CD11b) were detectable in the
peritoneum 4 and 24 hours after thioglycollate injec-
tion, with neither population detectable in resident cells
(0 h) or as inflammation was resolving (96 h after
thioglycollate injection) (Figure 2A). Neutrophils and
monocytes in the peritoneum stained positively for 11-
HSD1, with higher levels in neutrophils than in monocytes
(Figure 2B). Separation of neutrophils from other perito-
neal cells lavaged 24 hours after thioglycollate injection
A
B
Figure 3. Monocyte depletion has no effect on the induction of
11-HSD1 activity in thioglycollate-elicited peritoneal cells.
Diphtheria toxin was administered to DTR transgenic mice 24 hours
prior to the ip thioglycollate injection. Control mice were treated
with thioglycollate alone. Peritoneal cells were lavaged 4 hours after
the thioglycollate injection. A, May-Geimsa staining of
cytocentrifuged peritoneal cells showing elicited neutrophils and
monocytes from thioglycollate treated control mice (left panel), and
depleted numbers of monocytes in lavages from diphtheria toxin
(DT)-treated mice (right panel). B, 11-HSD1 activity was measured
as the percentage conversion of 200 nM [3H]-11-
dehydrocorticosterone (11-DHC) to corticosterone in 106 cells,
measured after 4 and 20 hours of incubation with [3H]-11-DHC.
White bars, controls; black bars, DTR transgenic mice. Photographs
are representative of two different mice of each group, and values
are mean  range of conversion for two mice/group.
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showed higher 11-HSD1 reductase activity (conversion
of 11-dehydrocorticosterone to corticosterone) and
mRNA levels in isolated neutrophils than in total cells or
the cells (mainly monocytes/macrophages), which re-
mained after removal of neutrophils (Figure 2, C and D).
Conversion of corticosterone to 11-dehydrocorticoster-
one was negligible in the peritoneal neutrophil population
(3.3% conversion of 200 nM corticosterone to 11-dehy-
drocorticosterone by 106 cells in 24 h), similar to previ-
ously reported background levels of dehydrogenase activ-
ity in total peritoneal cells (19).
To confirm that neutrophils are the main population
of cells expressing 11-HSD1 during peritonitis, we
used CD11b-DTR transgenic mice,
in which the CD11b promoter
drives the expression of the human
diphtheria toxin receptor, to selec-
tively ablate monocytes/macrophages
(25). Injection of diphtheria toxin 24
hours prior to thioglycollate markedly
depleted monocytes/macrophages (Fig-
ure 3) but had no significant effect on
11-HSD1 activity in peritoneal
cells lavaged 4 hours after the thiogly-
collate injection, consistent with
neutrophils being the high 11-
HSD1-expressing cell type in the
peritoneum at this time. Thus, al-
though 11-HSD1 is expressed in
monocytes/macrophages, neutro-
phils account for most 11-HSD1
activity in inflammatory cells re-
cruited during sterile peritonitis.
11-HSD1 expression in
neutrophils is elevated by
inflammation
We next asked whether inflammation per se increases
11-HSD1 levels in neutrophils. Within 4 hours after
the ip thioglycollate injection in mice, neutrophils were
depleted in the bone marrow (Figure 4A), with an in-
creased expression of 11-HSD1 in those that remained
(Figure 4B). The number of neutrophils in bone marrow
and their expression of 11-HSD1 returned to normal
levels 24 hours after the thioglycollate injection (Figure
4, A and B). In contrast, the number of neutrophils in the
blood was elevated 4 hours after thioglycollate injec-
tion, and despite normal blood neutrophil counts by 24
hours after the thioglycollate injection, 11-HSD1 expres-
sion remained elevated in these cells
(Figure 4, C and D). Similar to neu-
trophils, the number of monocytes in
the bone marrow was reduced 4
hours after the thioglycollate injec-
tion and normalized within 24 hours
(Supplemental Figure 3). In blood,
total monocyte number was reduced
4 hours and 24 hours after the thio-
glycollate injection (Supplemental
Figure 3). Moreover, 11-HSD1 ex-
pression was increased in 7/4hi and
7/4med blood monocytes 24 hours
after the thioglycollate injection
(Supplemental Figure 3).
A B
C D
Figure 4. 11-HSD1 is up-regulated in neutrophils in blood and bone marrow during
peritonitis. Neutrophil (Ly6G7/4CD11b) cell number was determined by flow cytometry
of freshly isolated (A) bone marrow (BM) and (C) blood from mice at various times after the
thioglycollate injection. 11-HSD1 MFI was measured in BM (B) and blood neutrophils (D)
using flow cytometry. Data are means  SEM and were analyzed by a one-way ANOVA
followed by Tukey’s post hoc tests. *, P  .05, **, P  .01, ***, P  .001, compared with 0
hours; §, P  .05, §§, P  .01, §§§, P  .001, compared with 4 hours (n  6 – 8/time point).
A B
Figure 5. 11-HSD1 inhibition augments peritonitis. Lavages were collected from UE2316
pretreated mice and vehicle pretreated mice (black bars) 4 hours after the thioglycollate
injection. Total peritoneal cell number (A) and the number of neutrophils (B) were greater in
lavages of UE2316-pretreated mice (white bars) than in lavages from vehicle-pretreated mice
(black bars). Data are means  SEM and were analyzed by a Student’s t test. *, P  .05
(n  9 –10).
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Inhibition of 11-HSD1 in vivo augments
peritoneal cell infiltration and enhances CD11b
surface expression on neutrophils during
peritonitis
To investigate whether 11-HSD1 activity affects neutro-
phil recruitment during peritonitis, compound UE2316, a
selective 11-HSD1 inhibitor, was administered prior to
the injection of thioglycollate. Addition of UE2316 to
peritoneal cells in vitro confirmed the inhibition of 11-
HSD1 activity in these cells (Supple-
mental Figure 4). Injection of
UE2316 alone did not elicit an in-
flammatory response, with no effect
on peritoneal cell number, compared
with vehicle (Veh) injected mice
(peritoneal cell count: Veh, 1.9 
0.3  106 vs UE2316, 2.0  0.4 
106 cells/mL). Because there were no
neutrophils or monocytes present in
the peritoneum in the absence of
inflammation, only experimental
groups that received thioglycollate
injection were compared. After the
ip injection of thioglycollate, mice
pretreated with UE2316 accumu-
lated more inflammatory cells in
the peritoneum (Figure 5A), in-
cluding more neutrophils (Figure
5B), than mice that received Veh
prior to thioglycollate injection.
There was no significant effect of
UE2316 on numbers of neutrophils
in bone marrow or blood after the
injection of thioglycollate (bone
marrow: Veh, 2.64  0.46  106
cells per femur vs UE2316, 2.51 
0.54  106 cells per femur (blood:
Veh, 3.68  0.76  106 cells/mL vs UE2316, 2.95 
0.54  106 cells/mL).
CellsurfaceexpressionofCD11b,an integrin familymem-
ber that regulates leukocyte adhesion and migration, is a
marker of neutrophil activation (28). By 4 hours after the
thioglycollate injection, cell surface levels of CD11b were
higher on the peritoneal neutrophils with prior inhibition
of 11-HSD1, compared with the mice pretreated with
vehicle (Figure 6A), probably through increased CD11b
mobilization to the cell surface
rather than an increase in newly syn-
thesized protein because Cd11b
mRNA levels were not increased in
peritoneal cells with inhibitor treat-
ment (Figure 6C). Levels of mRNA
encoding L-selectin, down-regulated
on activated neutrophils, showed a
trend (P  .10) to be lower in peri-
toneal cells with inhibitor treatment
(Figure 6D), again suggesting greater
neutrophil activation with 11-
HSD1 inhibition. There was no cor-
responding increase in cell surface
CD11b expression on the 7/4Ly6G
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Figure 6. 11-HSD1 inhibition enhances surface expression of adhesion molecule CD11b on
peritoneal neutrophils. Flow cytometry was used to measure surface expression of CD11b on
peritoneal cells lavaged 4 hours after the thioglycollate injection. A, CD11b MFI was higher
on the peritoneal neutrophils (7/4Ly6G) from mice pretreated with UE2316 (white bar)
than from mice pretreated with vehicle (black bar). B, No difference was found in surface
CD11b MFI on monocytes (7/4Ly6G) between the two groups. Data are means  SEM
and were analyzed by a Students t test. *, P  .05 (n  9 –10). Levels of mRNA encoding
CD11b (C) and L-selectin (D) were measured relative to mRNA encoding HPRT in peritoneal
cells lavaged 4 hours after the thioglycollate injection from mice pretreated with vehicle
(Veh, black bars) or UE2316 (white bars), with levels in Veh-treated mice arbitrarily set to
1.0. Data are means  SEM and were analyzed by a Student’s t test. *, P  .05 (n  8 –9).
HPRT, hypoxanthine-guanine phosphoribosyl transferase.
A B
Figure 7. 11-HSD1 inhibition reduces the expression of 11-HSD1 and annexin-1 during 4
hours of peritonitis. Quantitative PCR was performed on peritoneal cells collected 4 hours
after thioglycollate injection of mice pretreated with vehicle (Veh, black bars) or UE2316
(white bars). Levels of mRNA encoding 11-HSD1 (A) and annexin-I (B) were measured
relative to mRNA encoding HPRT, with levels in Veh-treated mice arbitrarily set to 1.0. Data
are means  SEM and were analyzed using a Student’s t test. *, P  .05 (n  8 –9). HPRT,
hypoxanthine-guanine phosphoribosyl transferase.
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monocyte population in the peritoneum 4 hours after the
thioglycollate injection (Figure 6B) or on blood or bone mar-
row neutrophils (Supplemental Figure 5).
Inhibition of 11-HSD1 in vivo reduces gene
expression of 11-HSD1 itself in thioglycollate
elicited peritoneal cells
Given the dynamic regulation of 11-HSD1 in neutro-
phils during the inflammatory response, levels of the en-
coding mRNA were measured in peritoneal cells 4 hours
after the thioglycollate injection, with pretreatment with
inhibitor or vehicle. Pretreatment with the 11-HSD1 in-
hibitor decreased levels of Hsd11b1 mRNA (Figure 7A),
suggesting autoregulation by glucocorticoids. Consistent
with lower intracellular levels of the glucocorticoid, levels
of Anxa1 mRNA, encoding annexin-I, substantially ex-
pressed in neutrophils and glucocorticoid inducible (29),
were also reduced in the thioglycollate-elicited peritoneal
cells after the inhibitor treatment (Figure 7B).
11-HSD1 is induced in human neutrophils by LPS
To investigate whether findings may extend to humans,
we treated human neutrophils with LPS, an acute inflam-
matory stimulus, for 4 hours. HSD11B1 mRNA, encoding
11-HSD1 was induced in all three samples tested (Figure
8), suggesting that in humans as in mice, 11-HSD1 is
induced in activated neutrophils to restrain inflammation.
Discussion
11-HSD1 is expressed in myeloid cells (neutrophils,
monocytes, macrophages, mast cells), but levels differ and
depend on cellular activation state. Here we have identi-
fied neutrophils as the inflammatory cells that highly ex-
press 11-HSD1 during sterile peritonitis. Inhibition of
11-HSD1 increased early neutrophil-dominated inflam-
matory cell recruitment. This is similar to 11-HSD1-de-
ficient mice, which show increased inflammatory cell re-
cruitment in sterile peritonitis and other models of
neutrophil-driven inflammation, including carageenan-
induced pleurisy, K/BxN serum-induced arthritis, and
early after myocardial infarction (20, 30). These findings
support an important role for 11-HSD1 in neutrophils in
restraining their accumulation at sites of sterile inflamma-
tion. Higher surface levels of CD11b and reduced expres-
sion of L-selectin suggest that 11-HSD1 inhibition may
reduce neutrophil rolling and increase neutrophil adher-
ence within blood vessels, promoting greater extravasa-
tion of inflammatory cells. In addition to decreasing sur-
face expression of CD11b (31), glucocorticoids suppress
neutrophil adherence and emigration, in part through in-
duction of annexin-1 (29). Consistent with the reduced
intracellular glucocorticoid action, Anxa1 expression
in peritoneal cells was decreased with 11-HSD1 inhi-
bition, suggesting the impaired ability to increase an-
nexin-1 levels is part of the mechanism that contributes to
increased acute inflammation with 11-HSD1 inhibition
or deficiency.
As previously observed in total peritoneal cells and
most other cell types, 11-HSD1 activity was solely re-
ductase with no dehydrogenase activity detected under
the conditions used. In vivo inhibition of 11-HSD1
reduced expression of the glucocorticoid-target gene,
Anxa1, in inflammatory cells lavaged from the perito-
neum early during inflammation when neutrophils pre-
dominate, consistent with reduced intracellular gluco-
corticoid reactivation. Our data are also consistent with
Hsd11b1 itself being a glucocorticoid target gene in
neutrophils because mRNA levels were decreased with
enzyme inhibition. Hsd11b1 mRNA levels are auto-
regulated in many cells, with tissue levels in vivo in-
creased under conditions of corticosterone excess (11,
17, 26). This feed-forward regulation of 11-HSD1
suggests that when the hypothalamic-pituitary-adrenal
axis is activated and substrate availability for 11-
HSD1 is increased (16), elevated levels of 11-HSD1 in
neutrophils will amplify glucocorticoid-mediated re-
straint of inflammation.
We observed a dissociation between levels of 11-
HSD1 protein (MFI) and the levels of the encoding
mRNA, with protein expressed under conditions in
which there is very little of the encoding mRNA. This
has been commented on previously (32, 33) and could
be due to a long protein half-life for 11-HSD1 but a
short half-life for the encoding mRNA. Our data sup-
port a long protein half-life. This situation would ensure
that 11-HSD1 protein is available to generate gluco-
corticoid if needed during an inflammatory response,
even after plasma corticosterone and 11-dehydrocorti-
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Figure 8. HSD11B1 mRNA is up-regulated in activated human
neutrophils. Human neutrophils were isolated from blood of three
healthy individuals and treated for 4 hours with 100 ng/mL LPS, prior
to RNA extraction and real-time measurement of HSD11B1 mRNA
levels. Values are normalized to levels in untreated cells (black bars)
and show fold induction of HSD11B1 mRNA after LPS (white bars) for
single individuals.
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costerone levels return to normal. Reduced intracellular
glucocorticoid regeneration (with reduced substrate
levels) will remove the feed-forward system that main-
tains high levels of Hsd11b1 mRNA under conditions of
glucocorticoid excess.
The presence of HSD11B1 mRNA has previously been
reported in human neutrophils (18). Our data show it is
up-regulated in human neutrophils in response to patho-
genic stimulation, suggesting 11-HSD1 may be impor-
tant in regulating neutrophilic inflammation in humans.
This highlights a possible side effect of 11-HSD1 inhi-
bition in humans. In clinical trials, selective 11-HSD1
inhibitors are effective and well tolerated. Phase II clinical
trials have shown a modest efficacy of selective 11-HSD1
inhibitors in the improvement of glycemic control in pa-
tients with type 2 diabetes (reviewed in reference 34).
Moreover, preclinical studies have suggested 11-HSD1
inhibition may be beneficial in atherosclerosis and in age-
related cognitive decline (34). Future clinical trials of 11-
HSD1 inhibition should be alert to situations in which
neutrophilic inflammation is likely.
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